Project Grant HT94252510559
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$783K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
This $1,046,250.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the Regents of the University of Minnesota in conducting a comprehensive research project titled "CHARACTERIZATION AND IN VIVO GENE THERAPY USING A NOVEL FANCONI ANEMIA MOUSE MODEL OF BONE MARROW FAILURE." The 3-year project, running from November 1, 2024 to October 31, 2027, will leverage the university's expertise in advanced...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,848,000.00 to the Regents of the University of Minnesota to conduct research on therapeutic targeting of aberrant mRNA polyadenylation in lethal prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in this critical medical domain. The...
This federal Project Grant award for $1,399,812.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant is awarded to the Regents of the University of Minnesota to conduct research on outcomes and late effects in pediatric and adolescent germ cell tumor survivors. This funding will enable...
This federal Project Grant award of $614,150.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Regents of the University of Minnesota to enhance the long-term persistence of Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cells for treating solid tumors. The award period runs from July 1, 2025 to June 30, 2027. As a prominent land-grant research institution, the University of Minnesota has a strong track record of...
The Regents of the University of Minnesota was awarded a $1,202,776 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2027 to map elements of DNA architecture responsible for malignant transformation in craniospinal sarcoma. Through this award, the University of Minnesota will conduct biomedical research to identify medical solutions for battlefield...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
This Project Grant award of $154,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Regents of the University of Minnesota to develop a dual-targeting G/D CAR-T cell therapy for the treatment of rhabdomyosarcoma. The award period runs from September 1, 2025 to August 31, 2027. The University of Minnesota, a prominent land-grant research institution, will leverage its extensive medical research capabilities to...
This $1,539,818.00 Department of the Army Medical Command federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420) will fund research led by the Regents of the University of Minnesota to develop multiplex edited, dual CAR gamma delta T cells targeting pediatric solid tumors. The three-year project, with a performance period from November 15, 2024 to November 14, 2027, seeks to advance innovative cell-based immunotherapies for the treatment of...
The federal Project Grant award of $1,059,132 from the Military Medical Research and Development program (CFDA 12.420) of the Defense Health Agency supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public. The award to the Regents of the University of Minnesota will fund a research project titled "NATURAL KILLER CELL-MEDIATED TARGETING OF IGF1R AND IR-A IN HORMONE RECEPTOR-POSITIVE BREAST CANCER" over the period of...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...